Degradation of the tumor antigen epitope gp100280-288 by fibroblast-associated enzymes abolishes specific immunorecognition

Biochimica et Biophysica Acta - General Subjects

Volumn 1671, Issue 1-3, 2004, Pages 59-69

  Albo, Federica ^a,b   Cavazza, Antonella ^a   Giardina, Bruno ^b   Marini, Mario ^a   Roda, L Giorgio ^a   Schumacher, Reto ^c   Spagnoli, Giulio C ^c  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

^b CATHOLIC UNIVERSITY   (Italy)

^c UNIVERSITY OF BASEL   (Switzerland)

Author keywords

Enzyme hydrolysis; Epitope; Human fibroblast; Tumor immunity; Vaccination

Indexed keywords

AMINO ACID; CARBOXYPEPTIDASE; EPITOPE; PROTEINASE; TUMOR ANTIGEN; TYROSYLLEUCYLGLUTAMYLPROLYLGLYCYLPROLYLVALYLTHREONYLALANINE; UNCLASSIFIED DRUG;

ARTICLE; CELL CLONE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DEGRADATION KINETICS; DRUG DEGRADATION; DRUG HYDROLYSIS; ENZYME ACTIVITY; FIBROBLAST CULTURE; HALF LIFE TIME; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUPERNATANT;

AMINO ACID SEQUENCE; AMINO ACIDS; AMINOPEPTIDASES; CARBOXYPEPTIDASES; CELLS, CULTURED; EPITOPES; FIBROBLASTS; HUMANS; MEMBRANE GLYCOPROTEINS; NEOPLASM PROTEINS; PEPTIDES; T-LYMPHOCYTES, CYTOTOXIC;

EID: 1542268340     PISSN: 03044165     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbagen.2004.01.006     Document Type: Article

References (41)

1. Houghton A.N. Cancer antigens: immune recognition of self and altered self. J. Exp. Med. 180:1994;1-4.
2. Boon T., Cerottini J.C., Vandeneynde B., Vanderbruggen P., Van Pel A. Tumor antigens recognized by T lymphocytes. Annu. Rev. Immunol. 12:1994;337-365.
3. Cox A.L., Skipper J., Chen Y., Henderson R.A., Darrow T.L., Shabanowitz J., Engelhard V.H., Hunt D.F., Slingluff C.L. Identification of a peptide recognized by five melanoma-specific human cytotoxic cell lines. Science. 264:1994;716-719.
4. Slingluff C.L., Yamshchikov G., Neese P., Galavotti H., Eastham S., Engelhard V.H., Kittlesen D., Deacon D., Hibbits S., Grosh W.W., Petro G., Cohen R., Wiernasz C., Patterson J.W., Conway B.P., Ross W.G. Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes. Clin. Cancer Res. 7:2001;3012-3024.
5. Osanto S. Vaccine trials for the clinician: prospect of tumor antigens. Oncologist. 2:1997;284-299.
6. Valmori D., Gileadi U., Servis C., Dunbar P.R., Cerottini J.C., Romero P., Cerundolo V., Levy F. Modulation of proteosomal activity required for the generation of a cytotoxic T lymphocyte-defined peptide derived from the tumor antigen MAGE-3. J. Exp. Med. 189:1999;895-906.
7. Oertli D., Marti W.R., Zajac P., Noppen C., Kocher T., Padovan E., Adamina M., Schumacher R., Harder F., Heberer M., Spagnoli G.C. Rapid induction of cytotoxic T-lymphocytes against melanoma associated antigens by a recombinant vaccinia virus vector expressing immunodominant epitopes and costimulatory molecules in vivo. Hum. Gene Ther. 13:2002;569-575.
8. Bellone M., Cantarella D., Castiglioni P., Crosti M.C., Ronchetti A., Moro M., Garancini P., Casorati G., Dellabona P. Relevance of the tumor antigen in the validation of three vaccination strategies for melanoma. J. Immunol. 165:2000;2651-2656.
9. Manickan E., Karem K.L., Rouse B.T. DNA vaccines - a modern gimmick or a boon to vaccinology? Crit. Rev. Immunol. 17:1997;139-154.
10. Boderke P., Merkle H.P., Cullander C., Ponec M., Bodde H. Localization of aminopeptidase activity in freshly excised human skin: direct visualization by confocal laser scanning microscopy. J. Invest. Dermatol. 108:1997;83-86.
11. Lee V.H.L. Enzymatic barriers to peptide and protein absorption. CRC Crit. Rev. Ther. Drug Carrier Syst. 5:1988;69-97.
12. Abergel C., Loret E., Claverie J.-M. Conformational analysis of T immunogenic peptides by circular dichroism spectroscopy. Eur. J. Immunol. 19:1989;1969-1972.
13. Rötzschke O., Falk K., Deres K., Schild H., Norda M., Metzger J., Jung G., Rammensee H.-G. Isolation and analysis of naturally processed peptides as recognized by cytotoxic T cells. Nature. 348:1990;252-254.
14. Ludewig B., McCoy K., Pericin M., Ochsenbein A.F., Dumrese T., Odermatt B., Toes R.E.M., Melief C.J.M., Hengartener H., Zinkernagel R.M. Rapid peptide turnover and inefficient presentation of exogenous antigen critically limit the activation of self-reactive CTL by dendritic cells. J. Immunol. 166:2001;3678-3687.
15. Alving C.R., Koulchin V., Glenn G.M., Rao M. Liposomes as carriers of peptide antigens: induction of antibodies and cytotoxic T lymphocytes to conjugated and unconjugated peptides. Immunol. Rev. 145:1995;156-162.
16. Nair S.K., Boczkowski D., Snyder D., Gilboa E. Antigen-presenting cells pulsed with unfractionated tumor-derived peptides are potent tumor vaccines. Eur. J. Immunol. 27:1997;589-597.
17. Hemberger A.B., Crotty L.E., Archer G.E., McLendon R.E., Friedman A., Dranoff G., Bigner D.D., Sampson J.H. Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma. J. Neuroimmunol. 103:2000;16-25.
18. Lau R., Wang F., Jeffery G., Marty V., Kuniyoshi J., Bade E., Ryback M.E., Weber J. Phase I trial of intravenous peptide-pulsed dendritic cells in patients with metastatic melanoma. J. Immunother. 24:2001;66-78.
19. Nair S.K., Snyder D., Rouse B.T., Gilboa E. Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts. Int. J. Cancer. 70:1997;706-715.
20. Jager E., Maeurer M., Hohn H., Karbach J., Jager D., Zidianakis Z., Bakhshandeh-Bath A., Orth J., Neukirch C., Necker A., Reichert T.E., Knuth A. Clonal expansion of Melan A-specific cytotoxic T lymphocytes in a melanoma patient responding to continued immunization with melanoma-associated peptides. Int. J. Cancer. 15:2000;538-547.
21. Salgaller M., Afshar A., Marincola F., Rivoltini L., Kawakami Y., Rosenberg S. Recognition of multiple epitopes in the human melanoma antigen gp100 by peripheral blood lymphocytes stimulated in vitro with synthetic peptides. Cancer Res. 55:1995;4972-4979.
22. Bakker A.B.H., van der Burg S.H., Huijbens R.J., Drijfhout J.W., Melief C.J., Adema G.J., Frigdor C.G. Analogues of CTL epitopes with improved MHC class-I binding capacity elicit anti-melanoma CTL recognizing the wild-type epitope. Int. J. Cancer. 70:1997;302-309.
23. 27-35 peptide: implications for peptide vaccines. Int. J. Cancer. 83:1999;326-334.
24. Blanchet J.S., Valmori D., Dufau I., Ayyoub M., Nguyen C., Guillaume P., Monsarrat B., Cerottini J.C., Romero P., Gairin J.E. A new generation of Melan-A/MART-1 peptides that fulfill both increased immunogenicity and high resistance to biodegradation: implication for molecular anti-melanoma immunotherapy. J. Immunol. 15:2001;5852-5861.
25. Widmann C., Maryanski J.L., Romero P., Corradin G. Differential stability of antigenic MHC class-I restricted synthetic peptides. J. Immunol. 147:1991;3745-3751.
26. Powell M.F., Grey H., Gaeta F., Sette A., Colon S. Peptide stability in drug development: a comparison of peptide reactivity in different biological media. J. Pharmacol. Sci. 81:1992;731-735.
27. Ayyoub M., Monsarrat B., Mazarguil H., Gairin J.E. Analysis of the degradation mechanisms of MHC class I-presented tumor antigenic peptides by high performance liquid chromatography/electrospray ionization mass spectrometry: application to the design of peptidase-resistant analogues. Rapid Commun. Mass Spectrom. 12:1998;557-564.
28. Amoscato A.A., Prenovitz D.A., Lotze M.T. Rapid extracellular degradation of synthetic class I peptides by human dendritic cells. J. Immunol. 161:1998;4023-4032.
29. 280-288 by the monocyte-like U937 cell line. Peptides. 24:2003;371-378.
30. Nicoletti I., Migliorati G., Pagliacci M.C., Grignani F., Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodidie staining and flow cytometry. J. Immunol. Methods. 139:1991;271-279.
31. Marini M., Urbani A., Bongiorno L., Roda L.G. Soluble enkephalin-degrading enzymes released by lymphomic and erythroleukaemic cell lines. Neurochem. Res. 17:1992;1155-1161.
32. Noppen C., Levy F., Burri L., Zajac P., Remmel E., Schaefer C., Luscher U., Heberer M., Spagnoli G.C. Naturally processed and concealed HLA-A21-restricted epitopes from tumor-associated antigen tyrosinase related protein-2. Int. J. Cancer. 87:2000;241-246.
33. Edelman R. The development and use of vaccine adjuvants. Mol. Biotechnol. 21:2002;129-148.
34. McWilliam A.S., Nelson D., Thomas J.A., Holt P.G. Rapid dendritic cell recruitment is a hallmark of the acute inflammatory response at mucosal surfaces. J. Exp. Med. 179:1994;1331-1336.
35. Babbitt B.P., Allen P.M., Matsueda G., Haber E., Unuanue E.R. Binding of immunogenic peptides to Ia histocompatibily molecules. Nature. 317:1985;359-361.
36. Sette A., Sidney J., Del Guercio M.F., Southwood S., Ruppert J., Dahlberg C., Grey H.M., Kubo R.T. Peptide binding to the most frequent HLA-A class-I alleles measured by quantitative molecular binding assay. Mol. Immunol. 31:1994;813-822.
37. Bouvier M., Wiley D.C. Importance of peptide amino and carboxyl terminal to the stability of MHC class I molecules. Science. 265:1994;398-402.
38. Lanzavecchia A., Sallusto F. Regulation of T cell immunity by dendritic cells. Cell. 106:2001;263-266.
39. Matzinger P. The danger model: a renewed sense of self. Science. 296:2002;301-305.
40. Roscetti G., Bongiorno L., Urbani A., Marini M., Roda L.G. Hydrolysis and binding of leucine enkephalin to lymphomic and erythroleukaemic cell lines. Int. J. Immunopharmacol. 12:1990;391-396.
41. Cochrane D.E., Carraway R.E., Boucher W., Feldberg R.S. Rapid degradation of neurotensin by stimulated rat mast cells. Peptides. 12:1991;1187-1194.